Effect of Gonadotrophin-Releasing Hormone Agonist Addition for Luteal Support on Pregnancy Outcome in vitro Fertilization/Intracytoplasmic Sperm Injection Cycles: A Meta-Analysis Based on Randomized Controlled Trials.
Gynecol Obstet Invest
; 85(1): 13-25, 2020.
Article
in En
| MEDLINE
| ID: mdl-31422404
ABSTRACT
PURPOSE:
The meta-analysis aimed to evaluate the effect of gonadotrophin-releasing hormone agonist (GnRH-a) addition for luteal support on pregnancy outcome in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) cycles.METHODS:
Meta-analysis.RESULTS:
A total of 3,584 cycles were identified from 13 randomized controlled trials. The cumulative analysis showed that GnRH-a addition for luteal supports significantly improved live birth rate (relative risk [RR] = 1.52; 95% CI 1.20-1.94; p = 0.0006), the clinical pregnancy rate (RR 1.21; 95% CI 1.11-1.33; p < 0.0001), ongoing pregnancy rate (RR 1.18; 95% CI 1.06-1.32; p = 0.004), pregnancy rate (RR 1.36; 95% CI 1.01-1.82; p = 0.04), implantation rate (RR 1.44; 95% CI 1.17-1.77; p = 0.0007), and multiple pregnancy rate (RR 1.40; 95% CI 1.04-1.88; p = 0.03) in comparison with control, but not for the incidence of ovarian hyperstimulation syndrome (RR 0.96; 95% CI 0.32-2.89; p = 0.94). We also found that GnRH-a addition for luteal support had a tendency to decrease the abortion rate (RR 0.72; 95% CI 0.56-0.93; p = 0.01).CONCLUSIONS:
Overall, the current meta-analysis showed a substantial efficacy of GnRH-a addition for luteal support on pregnancy outcomes in women undergoing IVF/ICSI and support the use of GnRH-a in luteal phase to improve the success of IVF/ICSI.Key words
Full text:
1
Database:
MEDLINE
Main subject:
Fertilization in Vitro
/
Gonadotropin-Releasing Hormone
/
Sperm Injections, Intracytoplasmic
/
Luteal Phase
Type of study:
Clinical_trials
/
Etiology_studies
/
Systematic_reviews
Limits:
Adult
/
Female
/
Humans
/
Pregnancy
Language:
En
Year:
2020
Type:
Article